Literature DB >> 16713191

Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

George G Zhanel1, Tamiko L Hisanaga, Nancy M Laing, Melanie R DeCorby, Kim A Nichol, Barb Weshnoweski, Jack Johnson, Ayman Noreddin, Don E Low, James A Karlowsky, Daryl J Hoban.   

Abstract

The North American Urinary Tract Infection Collaborative Alliance (NAUTICA) study determined the antibiotic susceptibility to commonly used agents for urinary tract infections of outpatient Escherichia coli urinary isolates obtained from various geographic regions in the USA and Canada. NAUTICA involved 40 medical centres (30 from the USA and 10 from Canada). From April 2003 to June 2004 inclusive, each centre submitted up to 50 consecutive outpatient midstream urine isolates. All isolates were identified to species level by each laboratory's existing protocol. Susceptibility testing was determined using the Clinical and Laboratory Standards Institute (CLSI) microdilution method. Ampicillin (resistant>or=32 microg/mL), sulphamethoxazole/trimethoprim (SMX/TMP) (resistant>or=4 microg/mL), nitrofurantoin (resistant>or=128 microg/mL), ciprofloxacin (resistant>or=4 microg/mL) and levofloxacin (resistant>or=8 microg/mL) resistance breakpoints used were those published by the CLSI. Of the 1142 E. coli collected, 75.5% (862) were collected from the USA and 280 (24.5%) were from Canada. Patient demographics revealed a mean age of 48.1 years (range, 2 months to 99 years), with female patients representing 79.4% of patients and males representing 20.6%. Overall, resistance to ampicillin was 37.7%, followed by SMX/TMP (21.3%), nitrofurantoin (1.1%), ciprofloxacin (5.5%) and levofloxacin (5.1%). Resistance rates for all antimicrobials were higher in US medical centres compared with Canadian centres (P<0.05). Fluoroquinolone resistance was highest in patients>or=65 years of age (P<0.05). Resistance rates demonstrated considerable geographic variability both in the USA and Canada. This study reports higher rates of antibiotic resistance in US versus Canadian outpatient urinary isolates of E. coli and demonstrates the continuing evolution of resistance to antimicrobial agents.

Entities:  

Mesh:

Year:  2006        PMID: 16713191     DOI: 10.1016/j.ijantimicag.2006.02.009

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  60 in total

1.  An 11-year analysis of the prevalent uropathogens and the changing pattern of Escherichia coli antibiotic resistance in 38,530 community urinary tract infections, Dublin 1999-2009.

Authors:  I M Cullen; R P Manecksha; E McCullagh; S Ahmad; F O'Kelly; R Flynn; T E D McDermott; P Murphy; R Grainger; J P Fennell; J A Thornhill
Journal:  Ir J Med Sci       Date:  2012-06-06       Impact factor: 1.568

2.  Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines.

Authors:  Claude Mambo Muvunyi; Florence Masaisa; Claude Bayingana; Léon Mutesa; André Musemakweri; Grégoire Muhirwa; Geert W Claeys
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 3.  [Urinary tract infections and antibiotic resistance].

Authors:  P Heisig
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

4.  Cystitis treatment in women, circa 2011: new role for an old drug.

Authors:  Henry J Schultz; Randall S Edson
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

Review 5.  Clinical importance and epidemiology of quinolone resistance.

Authors:  Eu Suk Kim; David C Hooper
Journal:  Infect Chemother       Date:  2014-12-29

Review 6.  Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.

Authors:  Laurel K Mydock-McGrane; Thomas J Hannan; James W Janetka
Journal:  Expert Opin Drug Discov       Date:  2017-06-02       Impact factor: 6.098

7.  Integrated Biosensor Assay for Rapid Uropathogen Identification and Phenotypic Antimicrobial Susceptibility Testing.

Authors:  Emanuela Altobelli; Ruchika Mohan; Kathleen E Mach; Mandy Lai Yi Sin; Victoria Anikst; Maurizio Buscarini; Pak Kin Wong; Vincent Gau; Niaz Banaei; Joseph C Liao
Journal:  Eur Urol Focus       Date:  2016-01-15

8.  Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.

Authors:  James A McKinnell; Nicholas S Stollenwerk; Chin W Jung; Loren G Miller
Journal:  Mayo Clin Proc       Date:  2011-05-16       Impact factor: 7.616

Review 9.  The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.

Authors:  Y-H Chen; W-C Ko; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-04       Impact factor: 3.267

10.  Risk factors for non-Escherichia coli community-acquired bacteriuria.

Authors:  M A Amna; B Chazan; R Raz; H Edelstein; R Colodner
Journal:  Infection       Date:  2012-10-11       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.